Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship?
Alberto Cereda, Milan-Italy, Cristina Conca, Lucia Barbieri, Giulia Ferrante, Gabriele Tumminello, Stefano Lucreziotti, Marco Guazzi, Antonio Mafrici
Abstract
Pharmacovigilance related to heart damage is of paramount importance at this early stage of massive coronavirus disease 2019 (COVID-19) campaigns to identify the profile of patients at risk. Systemic reactogenicity, which leads to systemic adverse events, often occur after the second dose. A possible explanation could be the molecular mimicry between SARS-CoV-2 viral proteins and cardiac structures or a nonspecific systemic inflammatory response secondary to vaccination (1).
Topics & Concepts
MedicineReactogenicityMyocarditisAdverse effectViral MyocarditisVaccinationCardiologyMolecular mimicryCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseInternal medicineIntensive care medicineImmunologyImmunogenicityInfectious disease (medical specialty)AntibodyHeparin-Induced Thrombocytopenia and ThrombosisViral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 Research